MHLW
Federal · Japan · 1-10 Employees
View Company Info for Free
Overview
Headquarters
580 Horikawacho Saiwai-ku, Kawasaki, Kan...Phone Number
+81 352531111Website
mhlw.go.jpRevenue
<$5 MillionIndustry
ZI Rank: 2
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
2
1
2
2
About MHLW
Japan Labour Health and Welfare Organization is a company that operates in the Federal industry. It employs 10000plus people and has 5GPlus of revenue. The company is headquartered in Kawasaki, Kanagawa, Japan.Explore more
MHLW Org Chart
YA
Director, Public Assistance Division, Social ...
AS
Deputy Director, Office of Nutrition
KM
Division Director, Tuberculosis & Infectious ...
YA
Division Deputy Director, Medical Device Eval...
MI
Global Assistant Director, Health Internation...
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is MHLW your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if MHLW has recently received funding, and reach out quickly before it becomes old news!
MHLW, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on MHLW recently announced quarterly report
Check out if MHLW is spiking on competitors!
Funding: Get notified immidiatlly once MHLW has new funding data
Product Launch: Get notified when MHLW launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Click to see if MHLW had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at MHLW
Recommended Actions
Find VP level buyers at MHLW
Find 2 more new buyers
Company Profile Activity
Activity Insights
MHLW is experiencing very low activity levels compared to other companies in the Government sector.
What does this means?
MHLW is drawing exceptional interest within the Government industry, suggesting notable developments or strong market momentum, learn more about MHLW.
MHLW Tech Stack
A closer look at the technologies used by MHLW
MHLW News & Media
HanAll Biopharma Announces Orphan Drug Designation for Batoclimab in Japan for Active Thyroid Eye Disease
Batoclimab receives Orphan Drug Designation in Japan, advancing treatment for active Thyroid Eye Disease (TED). Batoclimab, subcutaneous formulation, offers the potential for at-home administration, improving patient convenience and accessibility. Phase 3 study to confirm the potential of...Eisai: Metoject Subcutaneous Injection Pen (Methotrexate) Pen-Type Autoinjector Approved in Japan
TOKYO, Feb 16, 2024 - (JCN Newswire) - Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac Gesellschaft für klinische Spezialpräparate mbH announced that they have obtained manufacturing and marketing approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for the additional formulation of Metoject Subcutaneous Injection for the anti-rheumatic agent, pen-type autoinjector “Metoject® Subcutaneous Injection 7.5mg Pen 0.15mL, 10mg Pen 0.20mL, 12.5mg Pen 0.25mL and 15mYescarta® Now Approved in Japan for Initial Treatment of Relapsed/Refractory Large B-Cell Lymphoma
SANTA MONICA, Calif. & TOKYO--(BUSINESS WIRE)--Kite Pharma, Inc., a Gilead Company, (hereafter, Kite) (NASDAQ: GILD) and Daiichi Sankyo Co., Ltd. (hereafter, Daiichi Sankyo) (TSE: 4568) today jointly announced that the Japan Ministry of Health, Labour and Welfare (MHLW) has approved Yescarta (axicabtagene ciloleucel), a chimeric antigen receptor (CAR) T-cell therapy, for the initial treatment of patients with relapsed/refractory large B-cell lymphoma ( R/R LBCL): diffuse large B-cell lymphoma,Solasia Pharma: DARVIAS® Injection 135mg (Generic Name: DARINAPARSIN /Development Code: SP-02) Approved in Japan
TOKYO--(BUSINESS WIRE)--Solasia Pharma K.K. (TSE: 4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter “Solasia”) officially announced today that an organoarsenic drug “DARVIAS® Injection 135mg” (SP-02, hereinafter DARVIAS®) has been approved for relapsed or refractory Peripheral T-Cell Lymphoma (hereinafter “PTCL”) by the Ministry of Health, Labor and Welfare (MHLW). Solasia filed an NDA with the MHLW in Japan in June 2021. In October 2021, Nippon Kayaku Co., Ltd.
Read more news
Top Federal Companies
See more top companies
Frequently Asked Questions Regarding MHLW
Sign Up For FreeTo access detailed company insights
Japan Labour Health and Welfare Organization is a company that operates in the Federal industry. It employs 10000plus people and has 5GPlus of revenue. The company is headquartered in Kawasaki, Kanagawa, Japan.... Read More
